Cover Image

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population

In September 2023, 10-valent pneumococcal conjugate vaccine (PCV) was replaced by 15-valent PCV (PCV15) in Sweden's pediatric national immunization program. Following European approval of 20-valent PCV (PCV20) in March 2024, we assessed the cost-effectiveness of PCV20 versus PCV15, both under 2...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ann-Charlotte Fridh (Author), Andreas Palmborg (Author), An Ta (Author), Donata Freigofaite (Author), Sophie Warren (Author), Johnna Perdrizet (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
by: Derek Lytle, et al.
Published: (2023)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
by: Helen L. Stacey, et al.
Published: (2019)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024)

Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children
by: Josiah Ryman, et al.
Published: (2024)

Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Maria L. Avila-Aguero, et al.
Published: (2017)

Estimates on state-specific Pneumococcal Conjugate Vaccines (PCV) coverage in the private sector in the year 2012: Evidence from PCV utilization data
by: Habib Hasan Farooqui, et al.
Published: (2016)

Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Javier Nieto Guevara, et al.
Published: (2018)

Vaccination status (PCV13) of children with pneumococcal meningitis
by: Seidullayeva, Aliya, et al.
Published: (2020)

Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
by: Jorge A. Gómez, et al.
Published: (2022)

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
by: R. Rupp, et al.
Published: (2019)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
by: Patricia Izurieta, et al.
Published: (2022)

Closing the pneumococcal conjugate vaccine (PCV) introduction gap: an archetype analysis of last-mile countries
by: Preetika Banerjee, et al.
Published: (2023)

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
by: Paolo Castiglia, et al.
Published: (2017)

Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine
by: Timothy J. Chapman, et al.
Published: (2020)

Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012-2018
by: Larisa Savrasova, et al.
Published: (2021)

Tingkat Pengetahuan Orang Tua terhadap Penyakit Pneumonia dan Imunisasi Pneumococcal Conjugate Vaccine (PCV) di Indonesia
by: Erlika Saputri, et al.
Published: (2020)

Impact of PCV10 on pediatric pneumococcal disease burden in Brazil: time for new recommendations?
by: Daniel Jarovsky, et al.
Published: (2023)

Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009-2014
by: Michal Chowers, et al.
Published: (2017)

Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen
by: Josiah Ryman, et al.
Published: (2024)

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants
by: Shahrul Mt-Isa, et al.
Published: (2023)

Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review
by: Goran Bencina, et al.
Published: (2022)

The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019
by: Eiman Mokaddas, et al.
Published: (2021)

Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children
by: Catarina Silva-Costa, et al.
Published: (2023)

Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt
by: JP Sevilla, et al.
Published: (2022)

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
by: Masayoshi Shinjoh, et al.
Published: (2024)

Spatial variation and predictors of incomplete pneumococcal conjugate vaccine (PCV) uptake among children aged 12-35 months in Ethiopia: spatial and multilevel analyses
by: Aklilu Habte Hailegebireal, et al.
Published: (2024)

Decrease in Hospitalizations for Pneumonia in Children under Five Years of Age in an Indian Reservation in Panama after the Introduction of the Heptavalent Pneumococcal Conjugate Vaccine (PCV7)
by: Javier Nieto Guevara, et al.
Published: (2013)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023)

Changes in invasive pneumococcal disease serotypes in a regional area of Australia following three years of 7vPCV introduction
by: Fakhrul Islam, et al.
Published: (2012)

Decision-making for PCV in adults
by: John M. McLaughlin, et al.
Published: (2019)

Impact of PCV13 vaccination in Blantyre, Malawi
by: Portia Kamthunzi
Published: (2021)

Invasive pneumococcal infection due to serotype 15A after the pneumococcal conjugate vaccine implementation in Turkey
by: Ayşe Büyükcam, et al.
Published: (2017)

Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10
by: Germán Camacho Moreno, et al.
Published: (2020)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)

Reply to 'Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10'
by: Javier Nieto Guevara, et al.
Published: (2020)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
by: Yaru Shi, et al.
Published: (2023)

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024)

The economic impact of the switch from single- to multi-dose PCV13 vial in Benin
by: Patrick G. Ilboudo, et al.
Published: (2022)

Indirect effect and pneumococcal conjugate vaccines
by: L. Temimi
Published: (2009)